Archive for June, 2011

Clinical updates for ZCLS THLD. APPA raising cash. BCRX mixed shelf

Jun 29, 2011 No Comments by

BioCryst Pharmaceuticals, Inc (Nasdaq: BCRX) filed a mixed shelf to the value of $70m after hours yesterday. Zalicus Inc. (NASDAQ:ZLCS) today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA). Top-line results of the […]

Daily News Read more

PGNX files sNDA for Relistor. PTN initiates Phase 2b female sexual dysfunction

Jun 28, 2011 No Comments by

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the submission of a supplemental New Drug Application (sNDA) FDA requesting approval for the use of RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain. Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that enrollment of patients has commenced in […]

Daily News Read more


Jun 27, 2011 No Comments by

EpiCept Corporation (Nasdaq: EPCT) today announced that it has received initial written responses from the FDA regarding the its application for a Special Protocol Assessment (SPA) for Ceplene. Ceplene, which is administered in conjunction with low-dose interleukin-2 (IL-2), is its maintenance therapy for patients with acute myeloid leukemia (AML) in first remission. Among those responses, […]

Daily News Read more

PFE DRRX PTIE receive CRL for REMOXY. AEGR prices offering

Jun 24, 2011 No Comments

Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR) announced the pricing of the underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $15.50 per share. 3,250,000 of these shares are being offered by Aegerion and 1,000,000 of these shares are being offered by selling stockholders. DURECT Corporation (Nasdaq:DRRX) and Pain Therapeutics, Inc. […]

Read more

GTXI raises cash. ACHN HCV data due 4Q + PARD RGEN news

Jun 23, 2011 No Comments

GTx, Inc. (Nasdaq: GTXI) announced that it intends to sell 10m shares of its common stock in an underwritten public offering at $4.75 per share. Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) yesterday announced that it has initiated patient dosing in segment 2 of its Phase 2 clinical trial of ACH-1625 for the treatment of hepatitis C virus […]

Read more

Updates from ACHN LGND RNN

Jun 22, 2011 No Comments

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.90 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be […]

Read more


Jun 22, 2011 No Comments

Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS), announced today that the European Commission has granted marketing authorization for BYDUREON. They received a CRL in 2010 following their NDA submission in the US and plan to submit a response during 2H 2011. Threshold Pharmaceuticals, Inc. […]

Read more


Jun 20, 2011 No Comments

Pfizer Inc. (NYSE: PFE) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR) today announced the marketing approval of OXECTA. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common […]

Read more

SGEN Adcom July 14. AEGR PCYC offerings + ANX ASTM CTIC NGSX news

Jun 17, 2011 No Comments

ADVENTRX Pharmaceuticals, Inc (AMEX: ANX) shareholders yesterday approved the issuance of up to 13,478,050 shares pursuant to merger agreement with SynthRx, Inc. Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) announced that it has filed a registration statement relating to the underwritten public offering of 3,250,000 shares of its common stock and 1,000,000 shares of its common stock by […]

Read more

PPHM Ph2 NSCLC data, PLX to resubmit NDA soon, AVEO SPPI ADLR ALKS:

Jun 15, 2011 No Comments

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today reported median overall survival (MOS) of 12.4 months from a Phase 2 clinical trial evaluating bavituximab plus carboplatin and paclitaxel in patients with previously untreated, locally-advanced or metastatic non-small cell lung cancer (NSCLC). This survival is 20 percent longer than the 10.3 month MOS from a separate historic control […]

Read more

MITI promising Blinatumomab data. PARD to hold another reverse split vote

Jun 10, 2011 No Comments

Micromet (Nasdaq: MITI) released promising interim results from its Phase 2 single-arm trial of Blinatumomab for acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy. Data showed that 75% of patients (9 of 12) achieved a complete remission (CR) or CR with partial recovery of blood counts (CRh) following treatment with blinatumomab. […]

Read more